T. Rowe Price Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$161M Buy
5,590,504
+478,144
+9% +$13.8M 0.02% 480
2025
Q1
$171M Sell
5,112,360
-302,145
-6% -$10.1M 0.02% 455
2024
Q4
$277M Buy
5,414,505
+469,748
+9% +$24M 0.03% 366
2024
Q3
$253M Buy
4,944,757
+538,301
+12% +$27.5M 0.03% 391
2024
Q2
$197M Buy
4,406,456
+583,238
+15% +$26.1M 0.02% 419
2024
Q1
$179M Buy
3,823,218
+814,360
+27% +$38.1M 0.02% 442
2023
Q4
$107M Buy
3,008,858
+430,659
+17% +$15.3M 0.01% 527
2023
Q3
$76.7M Buy
2,578,199
+1,149,289
+80% +$34.2M 0.01% 562
2023
Q2
$25.8M Buy
1,428,910
+1,387,127
+3,320% +$25M ﹤0.01% 868
2023
Q1
$672K Sell
41,783
-10,148
-20% -$163K ﹤0.01% 1979
2022
Q4
$951K Sell
51,931
-9,704
-16% -$178K ﹤0.01% 1796
2022
Q3
$1.21M Buy
61,635
+7,228
+13% +$142K ﹤0.01% 1656
2022
Q2
$1.02M Buy
54,407
+16,824
+45% +$314K ﹤0.01% 1887
2022
Q1
$825K Sell
37,583
-39,239
-51% -$861K ﹤0.01% 2089
2021
Q4
$2.18M Buy
76,822
+10,659
+16% +$303K ﹤0.01% 1680
2021
Q3
$1.39M Buy
66,163
+238
+0.4% +$5.01K ﹤0.01% 1874
2021
Q2
$1.24M Buy
65,925
+17,060
+35% +$322K ﹤0.01% 1968
2021
Q1
$747K Sell
48,865
-32,037
-40% -$490K ﹤0.01% 2182
2020
Q4
$1.14M Sell
80,902
-5,166
-6% -$72.9K ﹤0.01% 1877
2020
Q3
$1.35M Hold
86,068
﹤0.01% 1679
2020
Q2
$1.51M Buy
86,068
+57,660
+203% +$1.01M ﹤0.01% 1626
2020
Q1
$418K Sell
28,408
-7,700
-21% -$113K ﹤0.01% 2059
2019
Q4
$906K Sell
36,108
-16,175
-31% -$406K ﹤0.01% 1924
2019
Q3
$786K Sell
52,283
-435,633
-89% -$6.55M ﹤0.01% 1912
2019
Q2
$12.2M Buy
487,916
+1,786
+0.4% +$44.7K ﹤0.01% 1281
2019
Q1
$11.1M Buy
486,130
+52,134
+12% +$1.19M ﹤0.01% 1303
2018
Q4
$13M Buy
433,996
+91
+0% +$2.73K ﹤0.01% 1262
2018
Q3
$12.4M Buy
+433,905
New +$12.4M ﹤0.01% 1337